The New York Academy of Sciences - logoThe Biochemical Pharmacology Discussion Group at the New York Academy of Sciences is presenting  a miRNA Symposium with a great speaker line-up:

EVENT:  MicroRNAs: A Gene Silencing Mechanism with Therapeutic Implications

WHEN: July 13, 2016  from 9am – 5:00 pm

The New York Academy of Sciences Conference Center in NYC
7 World Trade Center
250 Greenwich Street, 40th Floor
New York, NY 10007

Keynote Speaker

David Bartel, PhD


Maria Angelica Cortez, PhD
The University of Texas MD Anderson Cancer Center

Paul Grint, MD
Regulus Therapeutics

David S. Hong, MD
The University of Texas MD Anderson Cancer Center

Daniel J. Siegwart, PhD
University of Texas Southwestern Medical Center

Frank Slack, PhD
BIDMC Cancer Center/ Harvard Medical School

Joana Vidigal, PhD
Memorial Sloan Kettering Cancer Center


Here. Webinar is available.

The New York Academy of Sciences miRNA Symposium



And a second webinar this week presented by abcam:


Thursday, June 16, 2016
3pm-4pm CET / 2pm-3pm GMT / 9am-10am EST

Webinar Overview:

Drug‑induced cardiac injury (DICI) detection remains a major safety issue in drug development. While circulating microRNAs (miRs) have emerged as promising translational biomarkers, novel early detection biomarkers of cardiotoxicity are needed to evaluate toxicity in a time-dependent manner.

This webinar will review: [click to continue…]



Wednesday, June 15, 2016
3pm-4pm CET / 2pm-3pm GMT / 9am-10am EST


There are many different types of extracellular vesicles (EVs). Different subpopulations of exosomes, microvesicles and apoptotic bodies have been found to vary in size, composition and intracellular origin.

Within the last decade, cell-secreted EVs have been isolated from most of the fluids of the body, with many laboratories from around the world showing that their composition of lipids, proteins, messenger and micro RNAs are cell-type specific and subject to changes in pathological scenarios. As a result, EVs have been widely studied as a biological source to unravel low invasive biomarkers for predicting, diagnosing and monitoring diseases.
However, despite the many technological advances [click to continue…]


MirGeneDB logoMicroRNAs (miRNAs) are a novel class of gene regulators that are now the center of their own research field in human cancer: the non-coding RNA field. MiRNAs are ~22nt long non-coding RNA transcripts that derive from hairpin precursors and regulate gene-expression of target genes by inhibiting the protein production of the target genes’ messenger RNA (Jonas and Izaurralde 2015; Lin and Gregory 2015). Although much is known about miRNAs, with now nearly 40’000 scientific articles written about them alone, paradoxically defining what is and what is not a miRNA has been difficult, severely hampering studies on their potential roles in cancer, for example.

In order to enable researchers to accurately study the dynamics of the human miRNA landscape, an international  group under the lead of Professor Kevin J. Peterson (Dartmouth, US) and Dr. Bastian Fromm (Oslo, Norway) decided to revisit the available human miRNA complement (Kozomara and Griffiths-Jones 2014). Fromm et al established and then applied a set of consistent criteria for the annotation of miRNAs. This set was derived from numerous recent publications that elucidated details of miRNA maturation/processing in the cell (Auyeung, et al. 2013; Schirle and MacRae 2012; Schirle, et al. 2014a; Schirle, et al. 2014b; Seitz, et al. 2008; Suzuki, et al. 2015; Tsutsumi, et al. 2011). They show that less than a third of the 1,881 human miRBase entries are robustly supported as the products of miRNA genes. These robustly supported 523 human miRNA genes sequences are [click to continue…]


Ever had trouble explaining what you are doing? Now there is help…

If you haven’t seen it on our Facebook page yet:
Thanks go to Katharina Petsche who created a 3D medical animation about microRNAs‬ for her master graduation project.
Very Cool!


Workshop: “NGS and non-coding RNA data analysis”

March 5, 2014

The organizers are happy to announce the upcoming “NGS and non-coding RNA data analysis” workshop II (2014) 15-16 May, Plovdiv, Bulgaria The SeqAhead COST action BM1006 is organizing a 2 day workshop with presentations on non-coding RNA (ncRNA) research, bioinformatics, data analysis and stimulating discussions between biologists and bioinformaticians. The registration for this COST WS is now […]

Read the full article →

Discussion of miRNA Gene Expression Normalization Strategies

March 5, 2014

Researchers at the University of Oxford and the Scripps Research Institute recently published an article evaluating the use of several different RT-qPCR normalization strategies when profiling miRNA gene expression in mouse serum. In their research article entitled “Assessment of RT-qPCR Normalization Strategies for Accurate Quantification of Extracellular microRNAs in Murine Serum,” Roberts et. al. compare […]

Read the full article →

starBase update: deciphering Pan-Cancer patterns of miRNAs, lncRNAs, ceRNAs and RNA-binding proteins from TCGA 14 cancer types

February 8, 2014

StarBase has been updated to explore Pan-Cancer pattern of lncRNAs, miRNAs, RNA-binding proteins (RBP) and their regulatory networks (ceRNA, coexpression) by mining expression profiles of miRNAs, lncRNAs and mRNAs across 14 cancer types (>6000 samples) from The Cancer Genome Atlas (TCGA) Data Portal (all data available without limitations). StarBase provides the following Pan-Cancer Analysis Services: […]

Read the full article →

DiamiR Reports Validation of Two Families of Brain-Enriched microRNAs as Highly Promising Blood-Based Biomarkers of Mild Cognitive Impairment

January 2, 2014

MONMOUTH JUNCTION, NJ–(Marketwired – January 02, 2014) – DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative blood-based tests for detection and monitoring of neurodegenerative diseases and cancer, announced today the publication entitled “Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study” in Aging. Mild Cognitive Impairment is a […]

Read the full article →

Microlin Bio Inc. Licenses The Ohio State University’s miRNA Patent Portfolio to Advance Cancer Diagnostics & Therapeutics

September 26, 2013

COLUMBUS, Ohio, and NEW YORK, Sept. 26, 2013 /PRNewswire/ — The Ohio State University today announced the signing of an exclusive world-wide agreement with Microlin Bio Inc., licensing a large portfolio of Ohio State’s groundbreaking cancer discoveries. The portfolio includes nearly 100 issued and pending microRNA patents that could lead to entirely new, more effective and more targeted ways to diagnose and treat […]

Read the full article →